Vemurafenib Active Not Recruiting Phase 1 Trials for Malignant Melanoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01271803A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
NCT01910181A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
NCT01656642A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma